ArticleTranslational vision science & technology2026
Automated Identification and Segmentation of Diabetic Macular Edema Subtypes Using Deep Learning.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to develop a deep learning algorithm capable of accurately classifying diabetic macular edema (DME) subtypes and segmenting the lesions in patients with diabetic retinopathy (DR) using structural optical coherence tomography (OCT) images. Methods: We retrospectively collected 3120 DME OCT B-scan images from 823 eyes of patients with DME, acquired from 4 different spectral-domain and swept-source OCT devices (Topcon 3D-2000, Topcon Triton, BK400K UWF SS-OCT, and VG200 SS-OCT) to enhance device diversity and evaluate cross-device generalizability. An annotation team, consisting of two mid-career ophthalmologists and one senior retinal specialist, performed meticulous multi-label annotations, including DME subtype categories, detection bounding boxes, and pixel-level segmentation masks, to build the DME-Seg dataset. Based on this dataset, we fine-tuned the YOLO11x-Seg model for the detection and segmentation tasks. Results: The fine-tuned model achieved promising performance on the DME-Seg dataset. For lesion detection, it attained an average mAP50(B) of 0.82, mAP50-95(B) of 0.56, and Dice coefficients of 0.82 ± 0.20 (95% confidence interval [CI] = 0.81-0.83). For segmentation, it achieved an mAP50(M) of 0.84, mAP50-95(M) of 0.54, and Dice coefficients of 0.79 ± 0.18 (95% CI = 0.78-0.80). Conclusions: The constructed DME-Seg dataset and the validated model demonstrate promising performance in the automated detection and segmentation of DME subtypes, with encouraging cross-device generalization capability. This resource provides a foundation for advancing artificial intelligence (AI)-assisted diagnosis and personalized treatment planning for DME. Translational Relevance: This automated quantification tool bridges the gap between AI research and clinical utility by assisting ophthalmologists in the precise diagnosis and treatment of DME.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.